Synthesis, docking study and biological evaluation of novel N-(1,3-benzothiazole-2-yl)-2-(pyridine-3-ylformohydrazido) acetamide derivatives by Acharya, Prachi T et al.
 
 
Indian Journal of Chemistry 






Synthesis, docking study and biological evaluation of novel N-(1,3-benzothiazole-
2-yl)-2-(pyridine-3-ylformohydrazido) acetamide derivatives 
Prachi T Acharyaa, Divya J Jethavaa, Mahesh S Vasavaa, Zeel A Bhavsara, Manoj N Bhoib, Dhanji P Rajanic &  
Hitesh D Patel*a 
a Department of Chemistry, School of Sciences, Gujarat University, Ahmedabad 380 009, India 
b Plot no 18, Piramal Enterprises Limited, Pharmez, Matoda, Ahmedabad 382 213, India 
c Microcare Laboratory and TRC, Surat 395 003, India 
E-mail: drhiteshpatel1@gmail.com 
Received 22 December 2019; accepted (revised) 16 October 2020 
A series of N-(1,3-benzothiazole-2-yl)-2(pyridine-3-ylformohydrazido acetamide derivatives have been synthesized by 
facile and efficient conventional method. The structures of the compounds have been elucidated with the aid of elemental 
analysis, IR, ESI-MS, and 1H and 13C NMR spectral data. Molecular docking revealed that synthesized derivatives and 
target proteins are actively involved in the binding pattern and had a significant correlation with biological activity. 
Molecular dynamics studies have also been performed and ADME parameters for the synthesized compounds determined. 
Biological evaluation of all synthesized compounds have been carried out in vitro for their antibacterial, antituberculosis and 
antifungal efficacy against various bacterial and fungal strains and H37Rv. The different studies indicate that newly 
synthesized compounds possess moderate to good biological activities. 
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Due to the very high development of drug resistance 
against the existing antibacterial and antifungal drugs 
there is an urgent need of synthesis of privileged 
classes of heterocyclic compounds in the field of 
synthetic and medicinal chemistry. In spite of many 
significant progresses in the antimicrobial therapy, 
diseases which are very infectious caused by bacteria 
and fungi remain a very big worldwide issue1,2. Multi 
drug resistance (MDR) is an antimicrobial resistance 
shown by a family of microorganisms to multiple 
antimicrobial drugs3. In particular, the emergence  
of multidrug resistant strains of gram-positive  
bacterial pathogens such as methicillin resistant 
Staphylococcus aureus and Staphylococcus epidermis 
and Vancomycin-resistant enterococcus are problem 
of ever-increasing significance1,2. Multi drug 
resistance tuberculosis is a type of tuberculosis which 
occurs when the bacteria are resistant to the most 
powerful anti TB drugs called Isoniazid and 
Rifampin4. Mycobacterium tuberculosis is a bacteria 
which is responsible for the contagious disease called 
as tuberculosis. Generally it effects the lungs of the 
body called as a pulmonary TB, but in few case it can 
also effects other parts of the body also called as extra 
pulmonary TB. The authoritative symptoms of 
tuberculosis are fever, night sweats, blood containing 
sputum, etc.5 Drug resistance emerges when anti-TB 
medicines are used inappropriately, through incorrect 
prescription by health care providers, poor quality 
drugs, and patients stopping treatment prematurely. 
MDR-TB is treatable and curable by using second-
line drugs6. Poor chemotherapeutics and inadequate 
local control programme are the two major reasons 
that it is not possible to manage TB and thus leads to 
the emergence of drug resistant strains of MTB.  
Drug resistant TB is very difficult to cure. It takes  
18-20 months if the patient is responsive to the 
second line treatment regimen in a positive manner. 
This regimen is very costly to treat in comparison to 
fully drug sensitive TB. Currently available second 
line drugs are not very effective and moreover, cause 
side effects and therefore it is necessary to identify 
novel drug targets7. 
The calibre treatment for tuberculosis contains 
different types of drugs such as Isoniazid,  
Rifampin, Pyrazinamide and Ethambutol8. Marketed 
antituberculosis first line drugs and second line drugs 
shows in the Figure 1. TB and HIV co-infection 
occurs when people have both TB as well as HIV and 
in another scenario when people have active or latent 




TB disease. When people have both diseases at that 
time each disease speeds up the process of  the  other 
one. When people have HIV it increases the rate of 
latent TB to convert in to the active TB. It may 
happen in a country with a high prevalence of TB9. 
TB is one of the top 10 causes of death worldwide, 
which is caused by single infectious agent. It was 
evaluated that, in 2016, 1.30 million deaths among 
HIV negative people and 3,74,000 deaths among HIV 
positive people occur due to this disease10. Isoniazid 
also known as isonicotinylhydarazide is an antibiotic 
which is used for treatment of tuberculosis.  
An overview of the treatment of tuberculosis shows in 
the Figure 211. Isoniazid is frequently given with the 
drugs such as Rifampicin, Pyrazinamide either 
Ethambutol or Streptomycin12. 
Isoniazid is a prodrug. It is also called as pyridine-
4-carbohydrazide. In Mycobacterium tuberculosis it is 
 
 




Figure 2 — An overview of the treatment of TB 
 




activated by bacterial catalase- peroxidase enzyme13. 
Kat G catalysis the formation of the Isonicotinic acyl, 
radical which impulsively combines with NADH to 
form Nicotinoyl-NAD adducts. This complex binds 
tightly to the enoyl-acyl carrier protein reductase 
InhA, thereby blocking the natural enoyl- ACP 
reductase substrate and the action of fatty acid 
synthase. This process inhibits the synthesis of 
mycolic acids, which are required components of the 
mycobacterial cell wall14. Isoniazid may also be used 
for the nontuberculous mycobacterium such as 
M.avium, M.kansasii and M.Xenopi15. There is an 
urgent need to identify the new drug targets for the 
Mycobacterium tuberculosis and gradually develop 
the new drugs. Although Dots is a best treatment for 
TB still it takes minimum six months to cure. Due to 
the high incidence of MDR-TB Dots are failing to 
control the disease. These all drawbacks suggest that 
the design of newer and more potent antitubercular 
drugs with very less toxic effects for improved 
treatment of drug resistant and drug sensitive TB is 
indispensable16. The present investigation was aimed 
to find out new derivatives of Nicotinohydrazide 
(Pridine-3-carbohydrazide) with potent antibacterial, 
antifungal and antitubercular activities. Nicotine kills 
the insects very fast within an hour causing the 
intensive tremors, convulsions and then paralysis17. 
Nicotinic acid containing side chain on third position 
gives significant effect on toxicity to the insects18.  
Benzothiazole is one of the routinely obtainable 
heterocyclic compounds, which is basically found in 
alkaloids. It derived from terrestrial and marine 
natural products. Benzothiazole are an important class 
of bioactive and industrially important organic 
compounds19. From the recent literature, these 
derivatives are also known to possess antitubercular20, 
local anesthetic21, antidiabitic22, antiulcer23, 
antipsychotic24, antitumor25, antioxidant26, analgesic27, 
schistosomicidal28, antileishmanial29, anticonvulsant30, 
antiparasitic31, diuretic32, plant growth regulator 
activities33, anthelmintic34, Acaricidal35. 
Inspire by the significant biological activity of the 
structurally diverse heterocycles with fused 
heterocyclic systems along with active heterocyclic 
analogous. A series of N-(1,3-benzothiazole-2-yl)-
2(pyridine-3-ylformohydrazido acetamide derivatives 
were synthesized by facile and efficient conventional 
method (Table I). Biological evaluation of all 
synthesized compounds was studied In-vitro for their 
antibacterial, antituberculosis and antifungal efficacy 
against various bacterial and fungal strains and H37Rv. 
We have carried out molecular docking studies helped 
in revealing the mode of action of these compounds 
through their interactions with the active site of 
enzyme Enoyl-acyl-carrier protein reductase, is a key 
enzyme of the type II fatty acid synthesis (FAS) 
system ENR is a target for a narrow spectrum 
antibacterial drug discovery because the essential role 
in metabolism and its sequence conservation across 
many bacterial species. Molecular dynamics (MD) 
simulations may assistance to explain the binding site 
and time dynamics of interacting amino acid residues 
and to extend the information obtained from docking 
studies. We have also carried out in silico ADME 
prediction and Lipinski rules of 5 of synthesized 
Compounds. 
 
Results and Discussion 
 
Synthesis and structural characterization 
In the present work, novel substituted N-(1,3-
benzothiazole-2-yl)-2(pyridine-3-2(pyridine-3- 
ylformohydrazido) acetamide derivatives were 
prepared through a plausible conversion way. The 
synthetic route of N-(1,3-benzothiazole-2-yl)-
2(pyridine-3-2(pyridine-3- yl formohydrazido) 
acetamide derivatives delineated below as Scheme I. 
Initial analogue N- (1,3 benzothiazole-2-yl)-2 
chloroacetamide was synthesized from 1,3-
benzothiazole-2-amine. In the first step nucleophilic 
addition reaction occurs. The step occurs in two steps. 
In the first step nucleophilic attack on positive carbon 
atom by lone pair on Nitrogen atom on amine 1,3-
benzothiazole -2-amine reacts with CAC in presence 
of TEA which acts as a base for the preparation of 
acyl chloride. In the second step elimination reaction 
occurs. It happens in two steps first C=O bond 
reforms and the chloride ion removes from the 
reaction. It is followed by removal of hydrogen ion 
from nitrogen from Nicotinohydrazide producing 
HCl. Due to the mesomeric effect generated on the 
oxygen atom, the negative charge will be shifted 
towards CH3Cl and proton obtained from the reaction 
absorbed by K2CO3. And CH3Cl will be removed at 
the end of the reaction by producing final product. 
All the synthesized novel substituted N-(1,3-
benzothiazole-2-yl)-2(pyridine-3-2(pyridine-3-ylformo- 
hydrazido) acetamide derivatives were characterized 
by IR,
1
H NMR, mas spectroscopy, melting points and 
purification by crystallization using appropriate 
solvents. The IR spectrum of the 7a showed 
absorption at 3803 cm−1 which  is  due   to  the   -N-H 
























































































Reaction conditions: Int. (1 eq) Various Benzothiazole derivatives, CAC (1.5 eq), TEA (1 eq), K2CO3 (2.5 eq) 
 




stretching of amide. The compound showed 
absorption at 112 cm−1 which is due to C-NH-C 
stretching. The band appeared at 1670 cm−1 is due to -
C=O stretching confirmed the structure of the 
compound. 1H NMR (400 MHz, DMSO-d6): δ 9.54 
(s, 1H), 8.66 (s, 1H), 8.16 (d, J = 14.6 Hz, 2H), 8.09 
(s, 1H), 8.02 (s, 1H), 7.55 – 7.43 (m, 3H), 3.74 (d,  
J = 7.7 Hz, 2H), 3.32 (s, 1H); 13C NMR (100 MHz, 
DMSO-d6) δ 167.13 (s), 165.32 (s), 153.43 (s), 
151.38 (s), 150.91 (s), 149.45 (s), 137.58 (s), 134.41 
(s), 132.64 (s), 125.53 (s), 122.77 (d, J = 18.3 Hz), 
121.34 (s), 118.71 (s), 53.31 (s); EI-MS: m/z 328.01 
(M+1); IR (KBr): 3803 (N-H Aromatic), 3549 (C-H), 
1745 (C=C Aromatic), 1745 (C=O), 1323 cm−1 (C-N). 
 
In vitro biological screening 
 
In vitro antibacterial and antifungal activity 
This activity has been done at, Micro care 
Laboratory and TRC, Surat, India as per reported 
method
36,37
. All newly synthesized compounds were 
examined for antimicrobial activity against two gram 
negative bacterial strains (Pseudomonas aeruginosa 
MTCC 1688, Escherichia coli MTCC 443), two gram 
positive bacterial strains (Staphylococcus aureus 
MTCC 96, Streptococcus pyogenes MTCC 442) as 
well as three fungal strains (Aspergillus clavatus 
MTCC 1323, Candida albicans MTCC 227 and 
Aspergillus Niger MTCC 282) using the agar  
dilution method. Ampicillin, Ciprofloxacin and 
Chloramphenicol were used as standard control  
drugs for antibacterial activity, whereas Nystain and 
Greseofulvin were used for antifungal activity. 
The test must include a second set of the same 
dilutions inoculated with an organism of known 
sensitivity. Each synthesized compound was diluted 
obtaining 2000mg/mL concentration as a stock 
solution in primary screening 500, 250 and 
200mg/mL concentration of the synthesized 
compounds were taken. The active synthesized 
compounds found in the primary screening were 
further tested in a second set of dilution against all 
microorganisms. The compounds found active in 
primary screening were similarly diluted to obtain 
100, 62.5, 50 and 25 mg/mL concentrations. The 
highest dilution showing at least 99% is taken as MIC. 
The synthesized compounds (Table II) (7a-7i) 
investigated for their in vitro antibacterial activity. 
The bioassay results displays that compounds (7a-7i) 
succeed to show remarkable activity against the 
follow microorganisms. All novel synthesized 
compounds were investigated for them in-vitro 
antibacterial activity. The BioAssay result 
demonstrated that compounds (7a-7i) succeeded to 
indicate remarkable activity against below mentioned 
microorganism when compare to standard drugs. 
Among the gram negative bacterial strain S. aureus 
showed relatively higher sensitivity towards the tested 
compounds. In the view, analogue compounds 7d and 
7i (MIC 100 µg /mL) displayed good activity against 
S. aureus as compared to the standard drug Ampicillin 
(MIC 250 µg/mL). Compounds 7g and 7f (MIC 125 
µg/mL) also displayed good activity against S. aureus 
as compared to Ampicillin. Compounds 7b, 7g, 7e 
and 7h (MIC 250 µg/mL) were showing equipotent 
activity against S.aureus as compared to Ampicillin. 
For Pyogenes9 the best activity was exhibited by 
compound7f. (MIC 62.5 µg/mL) more potent to 
Ampicillin (MIC100 µg/mL). For E.Coli compounds) 
7g, 7e, 7d and 7h show good activity compare to 
(MIC100 µg/mL). All synthesized compounds were 
tested against In-vitro antifungal activity only once 
strain which is C.albicans show certain sensitivity 
 
 
Scheme I — Synthesis of the designed compounds 7a-i 
 




against some of the tested compounds, the rest of 
other two fungal strain were inactive to the same 
compounds. The derivatives were tested by using 
method as described by S.M.Prajapati[36]. The 
standard marketed drugs against the synthesized 
derivatives were Greseofulvin, Nystatin. Compounds 
7a, 7c, 7d, 7e, 7f and 7h show excellent activity 
against C.albicansas compared to the standard drug 
Greseofulvin. The graphical representation shows in 
the Figure 3 and Figure 4. 
 
In vitro Antituberculosis activity 
In vitro anti-tuberculosi0s of all the synthesized 
novel substituted N-(1,3-benzothiazole-2-yl)-2-
(pyridine-3-ylformohydrazido) acetamide derivatives 
against mycobacterium tuberculosis H37Rv strain  
was tested against Lowenstein-Jensen medium 
(conventional method) as described in A. Rattan37. 
Among the entire tested compounds compound 7a 
shows good activity against H37Rv strains by 
measuring the minimum inhibitory concentration 
(MIC µg/mL).Compounds 7g and 7i shows potent 
activity against the M.tuberculosis. Other compounds 
show negligible activity against M.tuberculosis. 
Biological activity of the compounds shown in the 
Table III. The graphical representation of all activities 
shown in the Figure 5. The graphical representation of 
Antimalarial activity shown in Figure 6. 
 
Structure Activity Relationship 
Observing the results, we could deduce valuable 
data about the structure activity correlations of the 
tested compounds. We have introduced different 
electron withdrawing groups and electron donating 
groups on different ring system such as Benzothiazole 
ring (6th position group such as -H, -Cl, -OMe,  
-F, -OH) during the synthesis. The electronic 
configuration of the various functional groups 
commanded to promising biological activity. it is our 
observation that the incorporation of electron 
withdrawing group like -Cl (sixth position on 
Benzothiazole) and -F group (Para position on 
benzoyl ring) in compound 7e, 7f it has yielded an  
Table II — Calculated ADME properties 














7a 76.796 −1.478 −6.283 187.347 116.463 −3.949 
7b 84.444 −1.638 −6.801 272.865 123.955 −5.135 
7c 79.382 −1.55 −6.34 222.288 124.332 −4.322 
7d 66.483 −1.967 −6.107 76.238 137.825 −3.949 
7e 80.444 −1.377 −6.443 194.22 115.912 −4.895 
7f 79.787 −1.373 −6.362 194.22 115.912 −4.895 
7g 77.95 −1.557 −6.664 198.708 115.596 −4.247 
7h 80.951 −1.63 −6.37 226.294 122.997 −4.458 
7i 79.742 −1.477 −6.226 244.07 123.574 −4.081 
Isoniazid 66.794 −0.843 −6.235 274.207 81.518 −5.235 
Ampicillin 17.36 −0.364 −5.369 254.36 152.23 −5.455 
Calculated using qikprop v.3.5. Range/recommended values calculated for 95% known drugs. 
 
 
Figure 3 — Graphical representation of the biological activity of 
the compounds (antibacterial activity) 
 
 
Figure 4 — Graphical representation of the biological activity of 
the compounds (antifungal activity) 
 





excellent activity against gram negative E. coli. 
Bacterial stain. Compounds possessing various 
functional group different ring system such as (-OH, 
OC2H6) also give good activity in E.Coli. 
Compounds 7a, 7c, 7d, 7e, 7f, 7g, 7h, and 7i  
showed very good activity against the bacterial  
stain S.aureus. When we introduced various group 
on Benzothiazole, the anti-bacterial activity 
decreased against P. Aeruginosa and S. Pyogenus 
(except compound 7f) due to function group.  
Only compound 7f shows good activity against  
S. Pyogenus. 
In case of anti-fungal biological screening, we 
have observed that the introduction of electron with 
drawing group like -F and electro donating group 
like -OH and -OMe at sixth position of compound 
7b, 7d, 7g, 7h, 7i the outstanding activity against  
C. albicans is observed. On the other side the 
antifungal activity decreased against A.niger and 
A.claveatus. In the case of anti-bacterial activity 
compounds 7a, 7g, and 7h contains good  
activity due to it contains functional groups such as 
(-H, and -OC2H5). 
Table III — Biological results of synthesized compounds 
Compd Antibacterial Activity Minimal 
Inhibition Concentration  
[mg/mL] 










































7a 500 250 125 125 1000 1000 1000 0.53 50 
7b 125 250 500 500 250 500 500 1.25 250 
7c 50 250 250 250 500 1000 1000 2.09 100 
7d 100 125 100 500 250 1000 1000 0.63 250 
7e 500 500 250 500 250 250 500 0.25 500 
7f 100 250 125 62.5 250 500 500 0.35 250 
7g 100 125 250 250 250 500 1000 1.24 62.5 
7h 100 100 100 125 1000 1000 1000 1.65 62.5 
7i 62.5 100 250 100 250 1000 >1000 1.28 100 
INH − − − − − − − − 0.20 
CHL 50 50 50 750 − − − − − 
AMP 100 − 250 100 − − − − − 
CIP 25 25 50 50 − − − − − 
NOR 10 10 10 10 − − − − − 
GEN 0.05 1 0.25 0.5 − − − − − 
NYS − − − − 100 100 100 − − 
GRE − − − − 500 100 100 − − 
Qui − − − − − − − 0.268 − 
Chlo − − − − − − − 0.020 − 
INH=Isoniazid, CHL=Chloramphenicol, AMP=Ampicillin, CIP=Ciprofloxacin, NOR=Norfloxacin, GEN=Gentamycin, NYS= Nystain, 




Figure 5 — Graphical representation of the biological activity of 
the compounds (antimalarial activity) 
 
 
Figure 6 — Graphical representation of the biological activity of 
the compounds (antituberculosis activity) 




In silico ADME Prediction and drug likeness study 
The ADME properties of the compounds were 
predicted by Jorgensen’s Method38 using Qikprop tool 
(Schrodinger) for novel molecules and the obtained 
values are provided in supporting data as Table II. 
Quinine, ampicillin and isoniazid are the reference 
drugs for the pharmaceutically relevant properties to 
assess the drug likeness and pharmacokinetic 
properties. 
All molecules have good pharmacokinetics 
properties (ADME). Most of the molecules found to 
have depicted decent human oral absorption 
percentage with in tolerable range (65-100%) and also 
good blood-brain barrier permeability (QP log BB) 
values within the suitable range of -3 to 1.5. All the 
compounds demonstrated great range IC50 value for 
HERG K+ channel blockage (QPlogHERG) below -5. 
Correspondingly all compounds have great intestinal 
Absorption Prediction as predicted value of Caco-
2cell permeability (QPPCaco) for the all compounds 
were found between (75-200nm/sec). Å assurances 
good influence on bioavailability of molecules. So the 
PSA values of the compounds were also obtained in 
the range of (70-200Å). The aqua solubility parameter 
(QPlogS) of the molecules also shows range  
between (-6.5-5). The indispensable pharmacokinetic 
parameters are established beside through their 
tolerated ranges in Table II. ADME prediction may 
found to expedite assessment of the appropriate 
molecules. In the present study, to find out the drug-
likeness characteristics, molecules were assessed 
using Lipinski’s rule of five showing zero violation of 
the rule (drug molecule should have molecular weight 
≤500, hydrogen bond acceptors, ≤10 and donor  
≤5, log P ≤5, polar surface area ≤140 Å)39. As rule  
of five compliance ensures the bioavailability.  
The values are provided in supporting data as 
Table IV. 
 
Molecular Docking Study 
Docking study was performed on the software 
called Schrodinger. It was performed on advance 
scientific programmed glide version 4.5. The program 
operated under Linux operating system installed on 
Intel with a 2.8 MHz Processor and 4GB RAM. 
Ligands were made by the tool which is called 
Ligprep-v2.140. 
Before docking process it is necessary to validate 
your docking tool Schrödinger molecular modelling 
package) and PDB target which we used. There are a 
number of methods available in literature41 for 
validating docking programs and scoring functions. 
We have carried out re-docking of cocrystallized 
native ligands into the active site of 1ENY, 4QRE and 
5HUT respectively using Schrodinger software for the 
validation of the docking process. The RMSD values 
of the native co-crystallized ligand after docking were 
0.199 (1ENY), 0.113 (4QRE) and 0.084(5HUT) Å, 
respectively which confirms the reliability of 
Schrodinger for docking compounds under study. 
Molecular docking of the synthesized molecules 
were studied against responsible enzymes i.e. enzyme 
Enoyl-ACP carrier protein (ACP) Reductase, S.aureus 
and C.albicans using PDB ID 1ENY, 4QRE, 5HUT 
correspondingly as respective inhibitors of such 
enzymes are found accountable for the potency. 
Enoyl-acyl-carrier protein reductase is a key enzyme 
of the type II fatty acid synthesis (FAS) system ENR 
is a target for a narrow spectrum antibacterial drug 
discovery because their essential role in metabolism 
and its sequence conservation across many bacterial 
species. ENR is a target for the Drug Isoniazid and 


















7a 327.36 2 8 1.567 0 
7b 357.386 2 8.75 1.782 0 
7c 371.413 2 8.75 2.374 0 
7d 343.359 3 8.75 1.103 0 
7e 361.805 2 8 2.142 0 
7f 345.35 2 8 1.875 0 
7g 327.36 2 8 1.868 0 
7h 357.386 2 8.75 1.719 0 
7i 371.413 2 8.75 2.026 0 
Isoniazid 137.141 3 4.5 −0.647 0 
Ampicillin 349.41 2 6 −2.004 0 
All values calculated by QikProp v 3.5 and the explanations of the descriptors are given in the text 
 




gene is inhA. Maestro software was hire for the 
identification of binding sites. All the calculation and 
numerical data were composed from maestro 
software, favourable binding poses between protein 
and simple van der Waals probes were finding at the 
automated prediction of the software, the top scoring 
predicted cavities was arranged in active sites directed 
docking studies. Default docking parameters and 
flexible space of novel N- (1,3-benzothiazole-2-yl)-
2(pyridine-3-ylformohydrazido) acetamide derivatives, 
were validated by docking parameters, which docked 
exactly in the cavities present in the different proteins 
( 1ENY, 4QRE, 5HUT) with an affinity of lower 
energetic compounds. Consequently, small molecule 
compounds with respect to low energetic molecules 
were docked using same docking parameters. Docking 
study was performed on single machine contain 8 GB 
RAM, 1 TB hard drive, operating system. Proteins 
were prepared on protein preparation wizard. Glide 
searches for favourable interactions between ligand 
molecules and protein receptor using a grid based 
method. Proteins were downloaded from protein 
databank few steps were performed  before  going  for 
docking. The steps are protein preparation, removing 
the water molecules having less than 3 hydrogen 
bonds, hydrogen bonding optimization, and adjusting 
the bond order for ligands protein. The resolutions of 
the proteins are 2.2Å, 1.7Å, 1.9Å respectively. The 
protein 1ENY was taken because Enoyl-acyl-carrier 
protein reductase is a key enzyme of the type II fatty 
acid synthesis (FAS) system ENR is a target for a 
narrow spectrum antibacterial drug discovery because 
the essential role in metabolism and its sequence 
conservation across many bacterial species. ENR is a 
target for the Drug Isoniazid and gene is inhA. The 
Global Stoichiometry of the protein is Homomer. 
inhA is the drug’s primary target. The Global 
Stoichiometry of the protein 4QRE is Monomer. The 
Global Stoichiometry of the protein 5HUT is 
Homomer. Molecular docking score of N-(1,3-
benzothiazole-2-yl)-2-(pyridine-3-ylformohydrazido) 
acetamide derivatives with PDB 1ENY (M. 
tuberculosis) shows in the Table IV. Binding poses of 
the compounds 7a and 7b are as described in the 
Figure 7. Compounds 7a and shows very good 
binding score as compared to the standard drug. The 
docking result shows that some of the synthesized 
derivatives had good affinity to the active site residue 
with respect to the standard reference drug 
Isoniazid.7a,7b,7d,7h and 7i shows better glide score 
as compared to the reference isoniazid with respect to 
crystal structure of M.Tuberculosis (PDB:1ENY). In 
this system compound 7b mainly interact with the 
amino acids such as GLY:96, LYS:165, PHE:41 and 
VAL:65.7a interact with the amino acids such as 
PHE:41, GLY:96, SER:94 and THR:196. Binding 
poses of the compounds having codes 7a and 7b 
shows in the Figure 7. 
The results of binding affinity obtained by 
molecular docking are shown in the Table IV. The 
binding affinity correlates with their in vitro activity. 
In depth analysis was done for the compounds, which 
shows the best activity in in vitro assay as well as 
good binding affinity in molecular docking studies. 
For the antituberculosis activity among all compounds 
7a showed better binding affinity (-8.423 Kcal/mol, 
Table V) as compared to that of the Isoniazid  
(-6.33 Kcal/mol, Table V). Similarly compound 7a 
showed good in vitro antituberculosis activity at  
the concentration of 50 µg/mL. The interaction of 
compound 7a with protein 1ENY (DNA gyrase), the 
binding site shown in Figure 7. 
Under in vitro antibacterial activity the compounds 
7b, 7c, 7e and 7i exhibited minimum zone of 
inhibition and good binding affinity to Protein 4QRE. 
The compound 7b compound has good binding 
affinity (-9.457Kcal/mol. Table V), which was 
comparable to Ampicillin (-4.947 K cal/mol Table V). 
Similarly compound 7b showed good in vitro 
antibacterial activity at the concentration of 125. The 
interaction of compounds 7b and 7c with protein 
4QRE (DNA gyrase), the binding site shows in 
Figure 8. In this system compound 7b mainly interact 
with amino acids such as GLN- 55, ASP-51, TYR-14, 
ASP-51 and ILE-12. Such as 7c compound mainly 
interact with amino acids GLN-55, ILE-12, TYR-14 
and ASP-51. The binding sites shown in the Figure 8. 
Under in vitro antifungal activity the compounds 
7a, 7c, 7e and 7f and 7iexhibited minimum zone of 
inhibition and good binding affinity to Protein 5HUT. 
The compound 7c compound has good binding 
affinity (-5.717 Kcal/mol, Table V), which was 
comparable to Nystain (-4.585K cal/mol Table V). 
Similarly compound 7c showed good in vitro 
antifungal activity at the concentration of 250. The 
interaction of compounds 7a and 7c with protein 
5HUT (DNA gyrase), the binding site shows in 
Figure 9 the interaction of compounds 7b and 7awith 
protein 5HUT (DNA gyrase), the binding site  
shows in Figure 9. In this system compound 7a mainly  







Figure 7 — Binding interaction of ligand 7a (A = 3D and 2D) and 7b (B = 3D and 2D) with Mycobacterium tuberculosis DNA complex 
(PDB: 1ENY) 
 
Table V — Docking score of the derivatives of novel N-(1,3-benzothiazole-2-yl)-2-(pyridine-3-ylformohydrazido) acetamide 






Entry Compd G-score XP HBond G-score XP HBond G-score XP HBond 
1 7a −7.126 −1.195 −8.342 −1.139 −4.768 −1.225 
2 7b −9.055 −1.029 −9.457 −0.35 −5.156 −0.998 
3 7c −6.351 −1.179 −9.817 −0.914 −5.717 −2.086 
4 7d −8.423 −1.160 −5.68 −0.932 −4.299 −0.998 
5 7e −6.541 −0.348 −8.987 −0.855 −5.177 −1.399 
6 7f −6.664 −0.749 −5.6 −0.17 −5.376 −1.821 
7 7g −6.903 −0.989 −6.8 −0.273 −3.958 −2.114 
8 7h −7.209 −1.133 −6.38 −0.665 −4.729 −1.187 
9 7i −7.994 −1.143 −8.191 −0.665 −5.981 −1.462 
10 INH −6.223 −0.993 N.T N.T N.T N.T 
12 AMP N.T N.T −4.947 −0.7 N.T N.T 
13 NYS N.T N.T N.T N.T −4.585 −1.93 
14 GRE N.T N.T N.T N.T N.T N.T 
INH=Isoniazid, AMP=Ampicillin, NYS= Nystain, GRE= Greseofulvin, N.T=NOT tested 
 




interact with amino acids GLY-96, THR-196 and 
PHE-41. 7c compound mainly interact with amino 
acids PHE-41, GLY-96 and LYS-165. The binding 
sites shown in the Figure 9. 
 
Materials and Methods 
All the required reagents and crude materials were 
procured from marketed sources and were utilized 
without any refinement. Completion of reaction and 
purity of all compounds were checked on coated thin 
layer chromatographic plates (TLC) plates 60245 
(Merck) used as stationary phase and (MDC: 
Methanol) (9.5:0.5) utilized as mobile phase and 
visualized under ultraviolet light. Melting points were 
taken from Optimelt MPA 100 melting point 
apparatus. FT-IR spectra were recorded on a Perkin 
Elmer FT-IR 377 spectrometer using KBr powder. 
1
H NMR was recorded on a Bruker AV400 MHz 
spectrometer using DMSO-d6 as a solvent and 
tetramethylsilane (TMS) as the internal reference. 
Mass spectra was recorded at Advion epression CMS, 
USA. Molecular study was performed using Glide on 
Schrodinger Maestro. ADME prediction was done on 




Synthetic Protocol of Targeted Molecules 
 
Synthetic procedure of N-(1, 3 benzothiazole-2-yl)-2 
chloroacetamide) (Intermediate), 6a-i 
In a 50 mL round bottomed flask (RBF), 1,3-
benzothiazole-2-amine (1.0mmol) was dissolved in 
25 mL of chloroform. In the same RBF add catalytic 
 
 
Figure 8 —Binding interaction of ligand: 7b (C = 3D and 2D) and 7c (D = 3D and 2D) with antibacterial (S. aureus) DNA complex 
(PDB: 4QRE cal representation of the biological activity of the compounds (antifungal activity) 
 




amount of triethyl amine (1.0mmol) (TEA). 
Chloroacetyl chloride (CAC) (1.5mmol) was added 
drop by drop in to the solution. After the addition of 
all components it was stirred for 15 minutes at 0°C. 
After 15 minutes the reaction was stirred under a 
reflux condition for 6 h. The reaction progress was 
monitored on TLC plate MDC: Methanol (9.5:0.5). 
After completion of the reaction, solvent was distilled 
out from the solution and the dark yellow precipitates 
of N-(1,3 benzothiazole-2-yl)-2 chloroacetamide thus 
obtained was used for further reaction. The reaction 
product was identified by comparing their spectral 
data. Product in good yield (80%). 
Dark yellow, mp 188-192°C; IR (KBr): 3361 
(C-H Aromatic), 3498 (N-H), 1745 (C=C Aromatic), 
1598 (C=O), 1323 (C-N), 869 cm−1 (C-Cl); 1H NMR 
(400 Hz, DMSO-d6): δ 8.01 (d, 1H), 8.18 (t, 1H), 
7.53 (t, 1H), 7.22 (d, 1H), 9.17 (s, 1H), 4.21 (s, 2H); 
EI-MS: m/z 227.01 (M+2). Anal. Calcd for 
C9H7ClN2OS: C, 47.60; H, 3.11; Cl, 15.64; N, 
11.29; O, 7.06; S, 14.15. Found C, 47.52; H, 
3.25; N,11.29; S, 14.12%. 
 
Synthetic procedure of novel N-(1,3-benzothaizol-
2-yl)-2-(pyridine-3-ylformohydrazido) acetamide 
derivatives [Step2], 7a-i 
In a 50 mL round bottom flask (RBF) N- (1, 3 
benzothiazole-2-yl)-2 chloroacetamide (1.0mmol) 
was dissolved in 25 mL of DMF and add K2CO3 in to 
the flask. After the addition of K2CO3 Pyridine-3- 
carbohydrazide was added slowly in to the flask. 
After 15 minutes the reaction was stirred under the 
reflux condition 12 h. The reaction progress was 
monitored on TLC plate Ethyl Acetate: Hexane (5:5). 
After completion of the reaction, solvent was distilled 
out from the solution and the dark brown precipitates 
of novel N-(1,3-benzothiazole-2-yl)-2(pyridine-3-
2(pyridine-3-yl-formohydrazido) acetamide obtained. 
 
 
Figure 9 — Binding interaction of ligand) 7a (E = 3D and 2D) and 7c (F = 3D and 2D) with Antifungal (C. albicans) DNA complex 
(PDB: 5HUT) 
 




The reaction product was identified by comparing 
their spectral data. Further products were confirmed 
by Spectral data (1H NMR, ESI-MS and IR). 
 
N-(1,3-benzothiazole-2-yl)-2-(pyridine-3-
ylformohydrazido) acetamide, 7a: Dark red solid, 
mp 159-162°C; IR (KBr) cm−1: 3803 (N-H 
Aromatic), 3549 (C-H), 1745 (C=C Aromatic), 1745 
(C=O), 1323 cm−1 (C-N); 1H NMR (400 MHz, 
DMSO-d6) δ 9.54 (s, 1H), 8.66 (s, 1H), 8.16 (d, J = 
14.6 Hz, 2H), 8.09 (s, 1H), 8.02 (s, 1H), 7.55 – 7.43 
(m, 3H), 3.74 (d, J = 7.7 Hz, 2H), 3.32 (s, 1H); 
13C NMR (100 MHz, DMSO-d6) δ 130.7 (C1), 135.3 
(C2), 125.1 (C3), 148.1 (C4), 148.7 (C6), 164.8 (C7), 
54.5 (C11), 168.5 (C12), 174.5 (C15), 153.2 (C17), 130.8 
(C18), 118.3 (C20), 125.3 (C21), 124.5 (C22), 121.8 (C23 
EI-MS m/z 328.01 (M+1). Anal. Calcd for 
C15H13N5O2S: C, 54.02; H, 3.00; N, 22.39; O, 
9.76; S, 10.11. Found C, 54.14; H, 3.00; 
N,21.39; S, 10.09%. 
N-(6, methoxy-1,3-benzothiazole-2-yl)-2(pyridine- 
3-ylformohydrazido) acetamide, 7b: Dark red, mp 
178.6-180°C; IR (KBr) cm−1: 3661 (N-H Aromatic), 
3336 (C-H), 2856 (C=C Aromatic), 1680 (C=O), 
1388 cm−1 (C-N); 1H NMR (400 MHz, DMSO-d6) δ 
9.54 (s, 1H), 8.66 (s, 1H), 8.16 (d, J = 13.7 Hz, 2H), 
8.00 (s, 1H), 7.79 (s, 1H), 7.53 (s, 1H), 7.11 (s, 1H), 
3.82 – 3.77 (m, 3H), 3.74 (d, J = 8.6 Hz, 2H), 3.33 (s, 
1H); 13C NMR (100 MHz, DMSO-d6) δ 130.7 (C1), 
135.3 (C2), 125.1 (C3), 148.1 (C4), 148.7 (C6), 164.8 
(C7), 54.5 (C11), 168.5 (C12), 174.5 (C15), 145.5 (C17), 
131.9 (C18), 118.3 (C20), 114.5 (C21), 156.7 (C22), 
104.9 (C23), 55.8 (C24). EI-MS m/z 357.01 (M+1). 
Anal. Calcd for C16H17N5O3S: C, 53.77; H, 
4.24; N, 19.60; O, 13.44; S, 8.99. Found C, 
54.60; H, 3.23; N, 18.60; S, 8.70%. 
N-(6, ethoxy-1,3-benzothiazole-2-yl)-2(pyridine-
3-ylformohydrazido) acetamide, 7c: Dark brown, 
mp 182-185°C; IR (KBr) cm−1: 3659 (N-H 
Aromatic), 3050 (C-H), 1469 (C=C Aromatic), 1653 
(C=O), 1479 cm−1 (C-N); 1H NMR (400 MHz, 
DMSO-d6) δ 9.43 (s, 1H), 8.63 (d, J = 13.3 Hz, 2H), 
8.19 (d, J = 10.8 Hz, 2H), 8.02 (s, 1H), 7.81 (s, 1H), 
7.50 (s, 1H), 7.13 (s, 1H), 4.12 – 3.97 (m, 2H), 3.94 
(s, 1H), 3.63 (s, 1H), 2.80 (s, 1H), 1.42 – 1.37 (m, 
3H); 13C NMR (100 MHz, DMSO-d6) δ 132.5 (C1), 
137.3 (C2), 127.5 (C3), 146.8 (C4), 148.7 (C6), 164.8 
(C7), 54.5 (C11), 168.5 (C12), 174.5 (C15), 144.8 (C17), 
131.5 (C18), 117.8 (C20), 114.7 (C21), 153.5 (C22), 
105.0 (C23), 64.6 (C24), 14.8 (C25). EI-MS m/z 372 
(M+1). Anal. Calcd for C17H17N5O3S: C, 54.97; 
H, 4.61; N, 18.95; O, 12.11; S, 8.90. Found C, 
53.80; H, 4.50; N, 18.55; S, 8.22%. 
N-(6, hydroxy-1,3-benzothiazole-2-yl)-2(pyridine- 
3-ylformohydrazido) acetamide, 7d: Dark brown, 
m.p 191-193°C; IR (KBr) cm−1: 3659 (N-H 
Aromatic), 3067 (C-H), 1450 (C=C Aromatic), 1653 
(C=O), 1379 cm−1 (C-N); 1H NMR (400 MHz, 
DMSO-d6) δ 9.43 (s, 1H), 8.63 (d, J = 13.5 Hz, 2H), 
8.19 (d, J = 12.0 Hz, 2H), 7.90 (s, 1H), 7.69 (s, 1H), 
7.50 (s, 1H), 7.03 (s, 1H), 4.95 (s, 1H), 3.94 (s, 1H), 
3.63 (s, 1H), 2.80 (s, 1H); 13C NMR (100 MHz, 
DMSO-d6): δ 132.5 (C1), 135.3 (C2), 124.5 (C3), 
144.8 (C4), 149.7 (C6), 168.8 (C7), 58.5 (C11), 168.5 
(C12), 177.3 (C15), 147.1 (C17), 135.5 (C18), 120.8 
(C20), 114.7 (C21), 163.5 (C22), 106.1 (C23). EI-MS m/z 
345 (M+1). Anal. Calcd for C15H13N5O3S: C, 
52.47; H, 3.82; N, 20.40; O, 13.99; S, 8.34. 
Found C, 52.44; H, 3.70; N, 20.22; S, 7.34%. 
N-(6,chloro-1,3-benzothiazole-2-yl)-2(pyridine-
3-ylformohydrazido)acetamide, 7e: Dark brown, 
mp.:182-185°C; IR (KBr) cm−1: 3644 (N-H 
Aromatic), 3055 (C-H), 1700 (C=C Aromatic), 1680 
(C=O), 1336 cm−1 (C-N); 1H NMR (400 MHz, 
DMSO-d6) δ 9.48 (s, 1H), 8.63 (d, J = 14.3 Hz, 2H), 
8.27 – 8.15 (m, 3H), 7.99 (s, 1H), 7.51 (d, J = 6.1 Hz, 
2H), 3.93 (s, 1H), 3.63 (s, 1H), 2.80 (s, 1H); 13C NMR 
(100 MHz, DMSO-d6) δ 130.7 (C1), 135.3 (C2), 125.1 
(C3), 148.1 (C4), 148.7 (C6), 164.8 (C7), 54.5 (C11), 
168.5 (C12), 175.3 (C15), 151.3 (C17), 132.3 (C18), 
118.3 (C20), 125.8 (C21), 129.8 (C22), 121.2 (C23). EI-
MS m/z 328.1 (M+2). Anal. Calcd for 
C15H12ClN5O2S: C, 40.79; H, 3.34; Cl, 9.80; N, 
19.36; O, 8.70; S, 8.16. Found C, 39.72; H, 
3.20; Cl, 9.90; N, 19.20; S, 8.15%. 
N-(6,fluoro-1,3-benzothiazole-2-yl)-2(pyridine-3-
ylformohydrazido)acetamide, 7f: White solid, mp 
160-166°C; IR (KBr) cm−1: 3644 (N-H Aromatic), 
3055 (C-H), 1700 (C=C Aromatic), 1680 (C=O), 
1336 cm−1 (C-N); 1H NMR (400 MHz, DMSO-d6): δ 
9.46 (s, 1H), 8.63 (d, J = 13.8 Hz, 2H), 8.19 (d, J = 
7.3 Hz, 2H), 8.00 (d, J = 34.6 Hz, 2H), 7.50 (s, 1H), 
7.27 (s, 1H), 3.93 (s, 1H), 3.63 (s, 1H), 2.80 (s, 1H);); 
13C NMR (100 MHz, DMSO-d6): δ 135.7 (C1), 140.3 
(C2), 131.1 (C3), 144.6 (C4), 152.7 (C6), 169.4 (C7), 
64.5 (C11), 162.5 (C12), 170.3 (C15), 148.3 (C17), 136.2 
(C18), 116.4 (C20), 123.1 (C21), 158.5 (C22), 108.0 
(C23). EI-MS m/z 345 (M+1). Anal. Calcd for 
C15H12FN5O2S: C, 52.17; H, 3.50; F, 5.60; N, 
20.28; O, 9.25; S, 9.28. Found C, 51.17; H, 
3.52; F, 5.55; N, 20.14; S, 8.18%. 





ylformohydrazido) acetamide, 7g: Dark red mp 
159-162°C; IR (KBr) cm−1: 3803 (N-H Aromatic), 
3549 (C-H), 1745 (C=C Aromatic), 1745 (C=O), 
1323 cm−1 (C-N); 1H NMR (400 MHz, DMSO-d6) δ 
9.48 (s, 1H), 8.91 – 8.72 (m, 2H), 8.23 (s, 1H), 8.11 
(s, 1H), 8.02 (s, 1H), 7.89 – 7.70 (m, 2H), 7.49 (d, J = 
1.1 Hz, 2H), 4.25 (s, 1H), 3.55 (s, 1H), 2.66 (s, 1H); 
13C NMR (100 MHz, DMSO-d6): δ 140.8 (C1), 121.7 
(C2), 149.7 (C3), 149.7 (C4), 121.7 (C6), 167.7 (C7), 
67.4 (C11), 168.5 (C12), 174.3 (C15), 158.3 (C17), 128.2 
(C18), 119.1 (C20), 125.3 (C21), 130.5 (C22), 121.8 
(C23). EI-MS m/z 328.01 (M+1). Anal. Calcd for 
C15H13N5O2S: C, 54.02; H, 3.00; N, 22.39; O, 
9.76; S, 10.11. Found C, 54.14; H, 3.00; N, 
21.39; S, 10.09%. 
N-(6, methoxy-1,3-benzothiazole-2-yl)-2(pyridine- 
4-ylformohydrazido) acetamide, 7h: Dark red, mp 
170.5-175°C; IR (KBr) cm−1: 3661 (N-H 
Aromatic), 3336 (C-H), 2856 (C=C Aromatic), 1680 
(C=O), 1388 cm−1 (C-N); 1H NMR (400 MHz, 
DMSO-d6) δ 9.42 (s, 1H), 8.91 – 8.72 (m, 2H), 8.24 
(s, 1H), 8.00 (s, 1H), 7.84 – 7.70 (m, 3H), 7.12 (s, 
1H), 4.25 (s, 1H), 3.83 – 3.78 (m, 3H), 3.55 (s, 1H), 
2.66 (s, 1H); 13C NMR (100 MHz, DMSO-d6): δ 
144.8 (C1), 129.2 (C2), 152.8 (C3), 152.8 (C4), 129.2 
(C6), 162.1 (C7), 58.4 (C11), 169.5 (C12), 177.3 (C15), 
145.5 (C17), 131.9 (C18), 118.2 (C20), 114.6 (C21), 
156.7 (C22), 104.9 (C23), 55.8 (C24). EI-MS m/z 357.01 
(M+1). Anal. Calcd for C16H17N5O3S: C, 53.77; 
H, 4.24; N, 19.60; O, 13.44; S, 8.99. Found C, 
54.60; H, 3.23; N, 18.60; S, 8.70%. 
N-(6, ethoxy-1,3-benzothiazole-2-yl)-2(pyridine-
4-ylformohydrazido)acetamide, 7i: Dark brown, 
mp 172-175°C; IR (KBr) cm−1: 3659 (N-H 
Aromatic), 3050 (C-H), 1469 (C=C Aromatic), 1653 
(C=O), 1479 cm−1 (C-N); 1H NMR (400 MHz, 
DMSO-d6) δ 9.42 (s, 1H), 8.90 – 8.72 (m, 2H), 8.24 
(s, 1H), 8.00 (s, 1H), 7.85 – 7.70 (m, 3H), 7.12  
(s, 1H), 4.25 (s, 1H), 4.12 – 3.97 (m, 2H), 3.55  
(s, 1H), 2.66 (s, 1H), 1.42 – 1.37 (m, 3H); 13C NMR 
(100 MHz, DMSO-d6): δ 141.8 (C1), 123.7 (C2), 150.1 
(C3), 150.1 (C4), 123.7 (C6), 169.4 (C7), 64.4 (C11), 
162.5 (C12), 178.3 (C15), 148.5 (C17), 131.1 (C18), 
118.2 (C20), 112.6 (C21), 158.7 (C22), 107.2 (C23), 64.6 
(C24), 14.8 (C25). EI-MS m/z 372 (M+1). Anal. Calcd 
for C17H17N5O3S: C, 54.97; H, 4.61; N, 18.95; 
O, 12.11; S, 8.90. Found C, 53.80; H, 4.50; N, 
18.55; S, 8.22%.Synthetic route of N-(1,3-
benzothiazole-2-yl)-2(pyridine-3-ylformohydrazido) 
acetamide derivatives is shown in the Table I. 
In vitro biological Screening  
We have carried out biological screening at 
Microcare Laboratory and TRC, Surat, India as per 
earlier reported methods36,37. All synthesized 
compounds were evaluated in-vitro for their 
antimicrobial efficacy against two gram positive 
bacterial strains (Staphylococcusaureus MTCC 96, 
Streptococcus pyogenes MTCC 442), two gram 
negative bacterial strains(Escherichia coli. MTCC 
443, Pseudomonas aeruginosa MTCC 1688) as well 
as three fungal strains (Aspergillus clavatus MTCC 
1323, Candida albicans MTCC 227 and Aspergillus 
Niger MTCC 282), anti-tubercular activity against 
H37Rv and anti-malarial efficacy against Plasmodium 
falciparum respectively. In antibacterial evaluation, 
ampicillin, was used whereas in antifungal evaluation, 
Greseofulvin and Nystain were used as standard 
control drugs. Isoniazid was used as a standard drug 




In-silico ADMET prediction and drug likeness study 
The pharmacokinetic parameters such as absorption, 
distribution, metabolism and excretion (ADME) were 
evaluated by using Qikprop tool of Schrodinger 
software for forecasting the drug-likeness properties of 
all synthesised molecules. This software package used 
for the exact possessions of molecules as compared 
with 95% of known drugs. It also assesses the 
fittingness of the compounds based on Lipinski’s rule 
of five for checking the drug like properties. Some 
other significant properties such as Lipinski’s rule of 5 
(molecular weight, hydrogen bond donor (Donor-HB), 
hydrogen bond acceptor (Accept-HB),octanol/water 
partition coefficient (QlogPo/w), aqueous solubility 
(QPlogS)) and ADMET. Parameter such as brain and 
blood partition co-efficient (QlogBB), percent human 
oral absorption were reflected for our present study to 
evaluate the potentiality of the drug. 
 
Molecular docking Study 
From the RCSB Protein Data Bank, protein 
structure coordinates (PDB Code 1ENY, 4QRE & 
5HUT were procured. The Glide score is calculated 
by using the following equation38:  
GScore = 0.065*vdW + 0.130*Coul + Lipo + 
Hbond + Metal + BuryP + RotB +Site 
Where, vdW denotes the van der Waals energy; 
Coul is the coulomb energy; Lipo denotes the 
lipophilic contact term; Hbond is the hydrogen-
bonding term; Metal is the metal binding term; BuryP 
represents the penalty for buried polar groups; RotB is 




the penalty for freezing rotatable bonds and Site is the 
polar interactions at the active site. 
 
Molecular Dynamics Simulation 
The coordinates of the best docking configurations 
of selected 1ENY-7a complexes were subjected to 
molecular dynamics simulation using Desmond 
simulation package of Schrödinger Materials Science 
Suite 2015-4. Molecular dynamics is a one type of 
modern tool to explore the interaction between 
inhibitor and protein. The simulation were applies on 
the molecule which had the best docking score which 
is 7a. MD simulations supported to have correct 
synchronizes for the molecular docking studies and 
structural variation have been found between the 
bound and unbound systems docked cavity of present 
ligand. 7a formed inhibitor bound and catalytic active 
site of PHE 41 and GLY 96. 7a show more flexibility 
during the simulation. Molecular dynamics was 
performed to find the best equilibrium confirmation. 
Ligand with the best docking score was selected for 
the analysis. Protein-ligand interactions (or 'contacts') 
are categorized into four types: Hydrogen Bonds, 
Hydrophobic, Ionic and Water Bridges. According to 
the interaction and forces 7a ligand fluctuated at some 
level yielding a RMSD value of 1.4Å. The analysis 
results of simulation are shown in the Figure 10, 
Figure 11, Figure 12, and Figure 13. (A-G).The input 
as well as output files were operated by Maestro 
graphical user interface application for Schrödinger 
Materials Science Suite 2015-2016. 
 
Conclusions 
In the summary novel series of novel substituted N-
(1,3-benzothiazole-2-yl)-2-(pyridine-3-
ylformohydrazido) acetamide derivatives were 
synthesized in very good yields. All the newly 
synthesized compounds 7a-7i were screened for 
antibacterial, antifungal, anti-tuberculosis activity and 
the results showed good activity in antibacterial and 
antifungal activities when compared with the standard 
drugs. In-vitro antibacterial data indicated that all 
compounds illustrated with appreciable antibacterial 
activity (MIC µg/mL) against Staphylococcus aureus 
(MTCC 96), and antifungal activity (MIC µg/mL) 
against Candida albicans (MTCC 227). Among the 
entire tested compounds compound 7a shows good 
activity against H37Rv strains by measuring the 
minimum inhibitory concentration (MIC µg/mL). 
Compounds 7g and 7i shows potent activity against 
the M.tuberculosis. Other compounds show negligible 
activity against M.tuberculosis. Among the gram 
 
 
Figure 10 — The Root Mean Square Deviations (RMSD) of 
backbone atoms relative to the starting complexes during 30 ns MD 
simulation of 1PFZ-12c. Each plot shows the RMSD of protein on 




Figure 11 — The Root Mean Square Fluctuation (RMSF) of 
complexes during 50 ns MD simulation of protein-1ENY 
 
 
Figure 12 — — Per-residues analysis of the representative 7a in 
complex with 1ENY. The analysis was based throughout the 30-
ns MD simulations. Hydrogen bond, hydrophobic, ionic and water 
bridge Protein-ligand interactions are illustrated by green, purple, 




Figure 13 — Desmond MD calculated protein (1ENY) − ligand 
7a contacts at the allosteric site region 
 




negative bacterial strain S. aureus showed relatively 
higher sensitivity towards the tested compounds.  
In the view, analogue compounds 7d and 7i (MIC  
100 µg /mL) displayed good activity against S. aureus 
as compared to the standard drug Ampicillin (MIC  
250 µg/mL). Compounds 7g and 7f (MIC 125 µg/mL) 
also displayed good activity against S.aureus as 
compared to Ampicillin. Compounds 7b, 7g, 7e and 
7h (MIC 250 µg/mL) were showing equipotent 
activity against S.aureus as compared to Ampicillin. 
All synthesized compounds were tested against  
In-vitro antifungal activity only once strain which is 
C.albicans show certain sensitivity against some of 
the tested compounds, the rest of other two fungal 
strain were inactive to the same compounds. The 
standard marketed drugs against the synthesized 
derivatives were Greseofulvin, Nystatin. Compounds 
7a 7c, 7d, 7e, 7f and 7h show excellent activity 
against C.albicans compared to the standard drug 
Greseofulvin. We have also done molecular docking 
studies with protein (PDB: 1ENY (M.tuberculosis), 
4QRE (S.aureus) and (5HUT) (C.albicans). In this 
study we designated interaction between ligand and 
protein. Biological activity and docking results of 
derivatives creates fascinating lead in drug 
development. The deliberate ADME parameters 
recommend good pharmacokinetic properties. 
Molecular dynamics simulation can be concluded that 
MD can be successfully fulfilled for new drug 
development. Overall this study discloses that active 
molecules are used as term plate for the development 
of active biological agents.  
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